TrialPath
Recruiting

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

NCT07556159 · Sanofi
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Hybrid Cross-sectional and Prospective Study to Assess Patient Characteristics, Disease Burden, Disease Control, Phenotypes, Endotypes, and Outcomes in a Real-world Setting in Patients With Asthma
About this study
The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life. The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.
Eligibility criteria
Inclusion Criteria: Applicable for Part 1 participants: * Age 6 years and older, at the time of signing the informed consent * Physician diagnosis of asthma for at least 12 months * Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps * Participant or legally authorized representative (where applicable) has consented to participate Applicable for Part 2 participants: * Age 18 years and older, at the time of signing the informed consent. * Physician diagnosis of asthma for at least 12 months * Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps * Participant or legally authorized representative (where applicable) has consented to participate * Participants must meet the criteria for at least one of the cohorts below: A) Asthma control cohorts 1. ACQ-5 \>= 1.5 2. ACQ-5 \< 1.5 (B) Type-2 biomarker cohorts 3. Elevated T2 biomarkers (B1: Type-2-high cohort) 4. Low T2 biomarkers (B2: Type-2-low cohort) Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants): * Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure * Participants with moderate/severe cognitive impairment. * Participants with moderate/severe cardiac disease. * Participants on immunosuppressive medication for a chronic condition. * Participation in other interventional and noninterventional clinical study (currently or in the past 3 months) The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Study design
Enrollment target: 2500 participants
Age groups: child, adult, older_adult
Timeline
Starts: 2026-04-01
Estimated completion: 2029-04-04
Last updated: 2026-04-29
Interventions
Other: Procedure: Investigational ProceduresOther: Procedure: Investigational Procedures
Primary outcomes
  • Part 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities (Part 1: At baseline)
  • Part 1: ACQ-5 Scores to Evaluate Characteristics of Participants With Asthma (Part 1: At baseline)
  • Part 1: Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Scores to Evaluate Characteristics of Participants With Asthma (Part 1: At baseline)
Sponsor
Sanofi · industry
With: Syneos Health
Contacts & investigators
ContactTrial Transparency email recommended-Toll free for US & Canada · contact · Contact-US@sanofi.com · 800-633-1610
All locations (4)
Clinical Research of California - Site Number: 840145Recruiting
Walnut Creek, California, United States
L&A Morales Healthcare, Inc - Site Number: 840102Recruiting
Miami, Florida, United States
Montana Medical Research - Site Number: 840137Recruiting
Missoula, Montana, United States
Pioneer Research Solutions - Site Number: 840104Recruiting
Houston, Texas, United States
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · TrialPath